Bright Minds Biosciences Inc Stock price
Compare with Peer Group
Is Bright Minds Biosciences Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 9,127 stocks worldwide.
Key metrics
Bright Minds Biosciences Inc Stock Analysis
Analyst Opinions
7 Analysts have issued a Bright Minds Biosciences Inc forecast:
Analyst Opinions
7 Analysts have issued a Bright Minds Biosciences Inc forecast:
Don't miss a Thing! We will send you all news about Bright Minds Biosciences Inc directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Bright Minds Biosciences Inc Stock News
Company Profile
Bright Minds Biosciences, Inc. is a biotechnology company, which engages in the development of therapeutics. The company is headquartered in New York City, New York. The company went IPO on 2021-02-08. The firm is focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other central nervous system (CNS) disorders. Its Serotonin (5-HT) is a neurotransmitter in the brain and modulates many biological functions. Dysfunction of serotonin receptors, transporters, and associated neurocircuits is fundamental to many diseases including epilepsies and neuro psychiatric. Its pipeline includes BMB-101, BMB-xxx, BMB-201, and BMB-202. The firm has a portfolio of patented, selective serotonin (5-HT2C, 5-HT2A and 5-HT2C/A-receptor subtypes) agonists that were identified by using high-throughput screening methods in combination with advanced molecular modeling techniques to interrogate the interaction between the drug and its targeted receptors to increase downstream signaling.
| Head office | Canada |
| CEO | Mr. Mcdonald |
| Website | brightmindsbio.com |


